Kornimate/medical-research-clean huggingface dataset:
appropriate gestational weight gain in overweight/obese women

Conditions: Gestational Weight Gain

Summary: the goal of this trial is to investigate the efficacy of a lifestyle intervention of healthy diet and physical activity for helping overweight/obese pregnant women to achieve appropriate gestational weight gain (gwg) for their prepregnancy body mass index (bmi). the goal of the intervention is to help women achieve the lower bound of the gwg range recommended by the institutes of medicine (iom) for a given prepregnancy bmi category (i.e., 11 lbs for obese women and 15 lbs for overweight women). the lifestyle intervention will be delivered via 2 in-person counseling sessions and 11 telephone contacts with study dieticians trained in motivational interviewing techniques. the lifestyle intervention will be compared to usual medical care. outcomes will be assessed by trained study personnel at approximately 10 weeks and 32 weeks gestation, within several days of delivery and at 6 months and 12 months postpartum.


Eligibility criteria:
inclusion criteria: * pregnant * pregravid bmi 25 to \<40 (as determined from a measured pregravid weight in electronic medical record) exclusion criteria: * diabetes * cardiovascular disease * gastrointestinal disease * bariatric surgery * lung disease * thyroid disease * eating disorder * cancer * bed rest or gestational diabetes in the current pregnancy * planning to get pregnant again or move within 1 year of delivery * substance abuse * serious mental health disorders

Keywords: gestational weight gain lifestyle intervention
pterygium head body mmc1: two different surgical procedures and their effect on endothelial cell count.

Conditions: Pterygium

Summary: to evaluate changes in endothelial cell count after pterygium surgery with mitomycin c (mmc) 0.02%

to evaluate the change in endothelial cell count in patients after pterygium surgery with mitomycin c (mmc) 0.02% for 2 minutes in 2 groups. * the control group: application of mmc after excision of the body of the pterygium without the head * the study group: application of mmc after excision of the body and the head of the pterygium

Eligibility criteria:
inclusion criteria: * males/females \>18 years old * pterygium with indication to operate * subjects that are able to sign an informed consent exclusion criteria: * recurrent pterygium/suspected tumor lesion * patients with endothelial cell diseases * patients after anterior segment surgery * patients with low compliance * patients without judgment ability * pregnancy * patients participated in another survey
clcf1 gene associated with postmenopausal osteoporosis of kidney yin deficiency syndrome

Conditions: Postmenopausal Osteoporosis

Summary: for nearly 112 million patients with osteoporosis in china, it is of great significance for preventing and treating by clearly understanding the molecular mechanism of kidney deficiency. thus, the research group has demonstrated in the earlier research that clcf1 is an associated gene that can regulate jak2/stat3 signal pathway and impact bone metabolism for kidney yin deficiency of postmenopausal osteoporosis (pmop). to make clear understanding of the direct-acting mechanism of clcf1 for bone metabolism, this study intends to: ①observe impacts of low expression of clcf1 upon immunities in mice and opg/rankl/rank signal system using the technology of adenovirus associated virus. ②explore impacts of over-expression and silencing of clcf1 on b lymphocytes by culcuturing the cells together with osteoblasts. ③ analyze the impacts of treating kidney yin deficiency of pmop by liuwei dihuang pill upon immunities and opg/rankl/rank system, and discuss the mechanism of regulating bone metabolism by clcf1 by opg/rankl/rank system via the bridge between immune system and bone metabolism, so as to demonstrate if the hypothesis of this study that "the molecular osteoimmunological mechanism of kidney yin deficiency of postmenopausal osteoporosis (pmop) is possibly closely related to the impacts of clcf1 regulation of opg/rankl/rank signal system on bone metabolism" is right or not.


Eligibility criteria:
inclusion criteria: * patients were included if they were female han chinese patients who had undergone natural menopause at least 2 years prior and * met the diagnostic criteria for osteoporosis according to the "clinical practice guidelines of traditional medicine for primary osteoporosis" * met the cm diagnostic criteria according to "syndrome differentiation in modern research of traditional chinese medicine" * provided informed consent, which was approved by the fujian academy of traditional chinese medicine clinical research ethics committee exclusion criteria: * patients who did not meet the diagnostic criteria for osteoporosis or cm standards * patients with rheumatoid arthritis, diabetes, secondary osteoporosis due to hyperthyroidism, and severe cardiovascular or cerebrovascular diseases * patients with abnormal liver and/or shen function test results * patients with osteoporosis who had received treatment with cm within the last month, hormone replacement therapy and calcitonin within the past three months, or bisphosphonates for 15 consecutive days within the past 6 months.

Keywords: osteoporosis kidney yin deficiency syndrome liuwei dihuang pill
head-to-head study of etelcalcetide (amg 416) and cinacalcet

Conditions: Secondary Hyperparathyroidism; Chronic Kidney Disease

Summary: the purpose of this study is to demonstrate that treatment with etelcalcetide (amg 416) is not inferior to treatment with cinacalcet for lowering serum parathyroid hormone (pth) levels by \> 30% from baseline among patients with chronic kidney disease (ckd) and secondary hyperparathyroidism (shpt) who require management with hemodialysis.


Eligibility criteria:
inclusion criteria: * eligible subjects must be receiving adequate thrice weekly maintenance hemodialysis with a dialysate calcium concentration ≥ 2.5 meq/l for at least 3 months prior to screening laboratory assessments * subjects must have shpt as defined by one central laboratory screening predialysis serum pth value \> 500 pg/ml, measured on separate days within 2 weeks prior to randomization * subjects must have one serum cca value ≥ 8.3 mg/dl obtained before dialysis within 2 weeks of the date of randomization * subjects receiving calcium supplements must have no more than a maximum dose change of 50% within 2 weeks before screening laboratory assessments are obtained, and the dose must remain unchanged through randomization exclusion criteria: * eligible subjects cannot have received cinacalcet during the 3 months preceding the first screening laboratory assessment * other criteria may apply

Keywords: secondary hyperparathyroidism, renal, kidney, kidneys, dialysis, hemodialysis, chronic kidney disease, ckd, shpt
intraarticular glucose versus hyaluronic acid injection for knee osteoarthrosis

Conditions: Osteoarthritis, Knee

Summary: the study is a prospective, randomized controlled, double-blind study. the enrolled patients were randomly divided into two groups: the intraarticular glucose group and the intraarticular ha group.

the glucose group underwent 3 sessions of 6cc 25% glucose injection with a 2-week interval between each treatment. the ha group was administered intra-articular ha ((hyruan plusr, average mw 3000 kd; lg life sciences ltd, korea)) for sessions with a 1-week interval between each treatment. the results were measured with the visual analogue scale (vas), western ontario and mcmaster universities osteoarthritis index (womac), and lequesne index. a baseline for each test was measured before treatment and then the effects of the treatments were measured by each test at 6 and 12 weeks after treatment

Eligibility criteria:
inclusion criteria: 1. people aged 45 years or more; 2. subjects diagnosed with knee oa according to the clinical criteria of the american college of rheumatology 3. subjects diagnosed with grade ii or iii oa during radiological examination as defined by the radiological classification of kellgren and lawrence (k-l) scale for knee oa 4. subjects with tenderness in the medial tibial plateau area exclusion criteria: 1. . subjects having other illnesses of neurologic diseases, cardiac disorders, hemodynamically unstable systems, or physical functions; 2. . inflammatory arthritis or subjects with acute knee arthritis 3. . subjects who have received intraarticular injection on the affected knee within the past 3 months. 4. . subjects with previous medical histories involving the affected knee such as surgeries, cancer and maligament tumors.
changes in eye shape with myopia management interventions

Conditions: Myopia

Summary: the goal of this clinical trial is to study changes in eye shape of nearsighted young adults using low-dose atropine eye drops or soft multifocal contact lenses. the main questions it aims to answer are: * do low-dose atropine and soft multifocal contact lenses affect the shape of the peripheral eye? * are changes in peripheral eye shape from these interventions influenced by changes in the focusing system of the eye? participants will: * have multiple different types of photos taken * have their prescription for glasses/contacts checked * have their eye health checked, including the use of dilating eye drops * be randomly assigned to use eye drops every night or wear special contact lenses daily instead of their typical contacts * will complete five study visits over the course of 12 months researchers will compare young adults using low-dose atropine to those wearing soft multifocal contact lenses and to those using no intervention to see if using these interventions affects retinal shape.


Eligibility criteria:
inclusion criteria: * best corrected visual acuity of 20/25 or better in each eye * nearsighted * current contact lens wearer * normal binocular vision (to be determined by an examiner at the first study visit) exclusion criteria: * eye diseases (including lazy eye or eye turn) * pregnant, nursing, or planning a pregnancy in the next 12 months * history of refractive surgery (e.g., lasik) * history of myopia control treatment * sensitivity to anesthetics or preservative in eye drops * difficulty with pupillary dilation
foam rolling and tissue flossing of the cuff muscles

Conditions: Ankle Injuries; Ankle Sprains

Summary: the hypothesis is that self-myofascial release (smr) intervention on the cuff muscles would affect positively sprint performance and jump height, as well as, decrease achilles tendon stiffness. the second hypothesis is that tissue flossing would be more effective than foam rolling. the participants will be randomly assigned to foam rolling, tissue flossing, and control group (without any intervention). after the intervention, repeated measures will be performed (15m sprint, countermovement jump (cmj) and achilles tendon stiffness). this will aim to improve sprint time, jump height and decrease tendon stiffness.

foam rolling provides beneficial results in ankle range of motion, muscle flexibility or muscle sourness. tissue flossing is popular in athletic training and physical therapy, as an effective strategy for ankle range of motion or performance. however, there is a lack of knowledge about the use of foam rolling and tissue flossing during a 60 minutes post-intervention examination on the performance and soft tissue stiffness. the main aim of this study is to investigate the effect of foam rolling and tissue flossing of the cuff on sprint performance, jump height and achilles tendon stiffness at different time points. the second aim is to assess the effectiveness of those self-myofascial release methods (smr). this study will include healthy, recreational active subjects aged between 20 and 25 years old.

Eligibility criteria:
inclusion criteria: * regular physical exercise activity (\~3 times per week). exclusion criteria: * experience with the application of foam rolling and tissue flossing. * current or prior pain or injury in the lower extremity. * previous history of surgery in the lower extremity. * cardiovascular disabilities.

Keywords: self myofascial release injury prevention performance athletic training
opioid reduction in orthopaedic surgery (oreos) - knees

Conditions: Knee Osteoarthritis; Chronic Post Operative Pain

Summary: knee replacements are the second most common surgery in canada. most patients recover very well but research consistently shows that 1 in 5 patients still have pain many months after surgery. doctors often prescribe opioid medications for pain after surgery (e.g. percocet, hydromorphone, codeine). these medications can be helpful for some people, but they can also be dangerous, particularly when used for a long time. many patients don't like the way opioids make them feel and would prefer alternative pain management strategies. some people become addicted to opioids, have a difficult time reducing the dose of opioids, or have lasting health problems after using them. people in this study will be randomized to either have usual care or a new pathway designed to improve pain control and decrease opioid use after knee replacements. this study will have an intervention coordinator who will assess patients before surgery and who will follow up with patients regularly after surgery to make sure their pain is controlled and to avoid long-term opioid use. this study will use education, physiotherapy, psychological therapy, ice/cold, and non-opioid pain medications. as pain medications may work differently in different patients, the coordinator will check on each patient to look for pain control and assist to reduce the amount of opioids used after surgery. this study will help people have safer and more effective pain management after surgery which may lead to better recovery, higher satisfaction, and a lower risk of being harmed by opioids after surgery.


Eligibility criteria:
inclusion criteria: * adult (18+) * undergoing elective total knee arthroplasty (tka) for knee arthritis * can use a simple electronic (phone or tablet) device * provide informed consent to participate exclusion criteria: * revision surgery * simultaneous bilateral arthroplasties * unable to consent (e.g., cognitive disability or substantial language barrier without a support person)

Keywords: total knee arthroplasty education opioid reduction cognitive behavioural therapy
fatty acid supplementation in children with asd (study 2)

Conditions: Autism Spectrum Disorder

Summary: the objective of the protocol is to test the impact of omega 3-6 on pre-specified biological signatures (il-1β, il-2, and ifnγ) and to correlate changes in the biological signatures with changes in asd symptoms.

children with asd suffer from both mental and physical symptoms that affect quality of life and severely disrupt family well-being. the objective of the protocol is to test the impact of omega 3-6 on pre-specified biological signatures (il-1β, il-2, and ifnγ) and to correlate changes in the biological signatures with changes in asd symptoms. fatty acid supplements are natural products with anti-inflammatory properties often used for treatment of asd symptoms, but the efficacy remains unproven.

Eligibility criteria:
inclusion criteria: * age 2-6 years old * asd diagnosis at nationwide children's hospital within the prior 6 months * english is primary language exclusion criteria: * fatty acid supplementation in the past 6 months * consumes fatty fish more than 3 times per week * still breastfeeding or formula feeding * quadriparesis * deafness * blindness * seizure disorder diagnosis * autoimmune disorder including type 1 diabetes, fragile x, rett, angelman syndromes, tuberous sclerosis * feeding problems precluding consumption of the supplement * ingredient allergy (canola, fish, or borage seed) * planned surgeries scheduled within the time frame of trial participation
the atlanta first in man study of the catania stent

Conditions: Coronary Artery Disease

Summary: to evaluate the short-term and mid-term safety and efficacy of the catania coronary stent for the treatment of up to two de novo lesions in native coronary arteries.

this is a prospective, non-randomized, first-in-man single center study. the study requires a 55 patients with documented myocardial ischemia undergoing pci.

Eligibility criteria:
inclusion criteria: * lesion length ≤ 20 mm * vessel size ≥ 2.5 ≤ 3.5 mm exclusion criteria: * life expectancy \< 1 year * left ventricular ejection fraction (lvef) \<30% * anti-thrombotic drug intolerance

Keywords: coronary stent
high(deadlift) versus low intensity motor control exercises on low back pain

Conditions: Low Back Pain

Summary: the aim of the study is to evaluate and compare the effects of high-intensity (deadlift) versus low-intensity motor control exercises on selfrated pain, function and symptoms on patients with peripherally mediated pain


Eligibility criteria:
inclusion criteria: * low back pain over 3 month * the pain must originate locally from the lowe back and be nociceptive exclusion criteria: -

Keywords: deadlift motor control exercises pain function functional capacity
arnica montana and bromelain in rhinoplasty

Conditions: Wound Healing

Summary: the purpose of this study is to assess the perioperative use of arnica montana and the combined use of arnica montana and bromelain in aiding the body's wound healing functions during the postoperative period after rhinoplasty. the secondary objective of the study is to determine if there is a reduction in postoperative edema when arnica montana and bromelain are combined. another secondary objective is to demonstrate increased patient satisfaction with the use of arnica montana and the combination arnica montana and bromelain.


Eligibility criteria:
inclusion criteria: -adults scheduled for outpatient primary rhinoplasty with osteotomies at boston medical center exclusion criteria: * oral or contact allergies to arnica montana or to derivatives from the ananas comosus or to any other member of the asteraceae family of plants such as ragweed, chrysanthemums, marigolds, and daisies or bromelain as determined by self disclosure. * allergies to pineapple as bromelain is from pineapple extract * currently taking antiplatelet medication or anticoagulation medications * chronic use of nsaids meaning those currently using nsaids daily for at least 3 months * taking other homeopathic remedies during the perioperative period * bleeding disorders as determined by self-disclosure or strong family history, patients in question who would like to participate in the study will have blood work obtained prior to operation * chronic medical conditions such as significant pulmonary, cardiac, liver, or kidney disease are excluded including poorly controlled hypertension or patients on more than one antihypertensive agent and patients with diabetes * malignancy, infection, immunodeficiency, metabolic syndrome, infectious, or inflammatory gastrointestinal disease * severe liver or kidney disease * significant psychiatric disorders * females who are breast feeding or pregnant * history of nasal surgery * history of head and neck malignancy * taking oral corticosteroid therapy * undergoing additional surgery other than primary rhinoplasty

Keywords: rhinoplasty arnica montana bromelain body healing post op rhinoplasty outcome evaluation
multicenter pilot-study for the therapy of medulloblastoma of adults

Conditions: Medulloblastoma

Summary: the purpose of this study is to determine whether a combination of a radiochemotherapy (vincristin) and a following maintenance chemotherapy (vincristin, cisplatin and ccnu) in adult patients with medulloblastoma is tolerable.

as medulloblastoma in adult patients are very rare (1.1% of all brain tumors), adults are often treated in the scope of expanded access treatments or within pediatric studies; although, it is not known whether medulloblastomas act in the same way in adulthood and in childhood. this is the first study to investigate the significance of a combination of a radiochemotherapy (vincristin) and a following maintenance chemotherapy (vincristin, cisplatin and ccnu) in adult patients with medulloblastoma with the purpose to have a starting point for the development of chemotherapeutical protocols in adults.

Eligibility criteria:
inclusion criteria: * age \> 18 years * medulloblastoma (+/- postoperative residual tumor, m0) or medulloblastoma (+/- postoperative residual tumor, m1-m3) respectively * primary diagnosis of the tumor * no previous chemo- or radiation therapy * karnofsky-index ≥ 70% * wbc ≥ 3000/μl; thrombocytes ≥ 100 000/μl; hb ≥ 10 g/dl * creatinine =\< 1,5 uln; bilirubin =\< 1,5 uln; gpt, got, ap =\< 2,5 uln * hiv and hepatitis b/c negative * no factors / any medical condition affecting patient's compliance * patient needs to fulfil protocol's requirements * patient is willing to use highly effective methods of contraception during dosing and for 6 months after the last dose; women of child-bearing potential must have a negative hcg laboratory test at baseline; pregnancy tests must be repeated every 4 weeks * patient's written consent exclusion criteria: * age \< 18 years * histologically not confirmed medulloblastoma * by chemo- or radiotherapy treated recidive tumor * other cancer (with exception of surgically cured carcinoma in situ of the cervix and non-melanocytic skin tumors) * hypersensitivity or contraindication against one of the used drugs * current or planned participation to another clinical trial during this study any other condition which, in the opinion of the investigator, would make the patient unsuitable for enrolment or could interfere with the patient participating in and completing the study * any medical condition associated with high medical risk or contraindicated to use chemotherapeutic agents as indicated in current product package insert * pregnant or nursing (lactating) women; women or men not willing to use a highly effective methods of contraception

Keywords: medulloblastoma cns malignant neoplasm noa neuroectodermal tumor vincristin ccnu cisplatin
clinical efficacy and safety of a laparoscopic sleeve gastrectomy in obese patients

Conditions: Obesity

Summary: this study aim to evaluate the clinical efficacy and safety after laparoscopic sleeve gastrectomy in patients with obesity. 300 patients with obesity and 49 healthy individuals with normal bmi were enrolled.

this study aim to evaluate the clinical efficacy and safety after laparoscopic sleeve gastrectomy in patients with obesity. 300 patients with obesity and 49 healthy individuals with normal bmi were enrolled. all patients with obesity underwent lsg. a multidisciplinary team evaluated participants with obesity at baseline, 1, 3, 6, 12, 24, and 36 months after lsg. anthropometrics, metabolic indicators, sex hormones, menstruation，glucose-lipid metabolic markers, and hepatic steatosis assessed by fibroscan(cap value and e value) were measured baseline and postoperative.

Eligibility criteria:
inclusion criteria: 1) age ranged from 16\~65 years old, 2) bmi over 37.5 kg/m2, or bmi over 32.5 kg/m2 with diabetes which meets the recommended cutoff for bariatric surgery of the guidelines for surgical treatment of obesity accompanied with or without type 2 diabetes in china. - exclusion criteria: * 1) secondary cause of obesity such as hypothalamic obesity, cushing syndrome, and hypophysis dysfunction, etc., 2) pregnancy or lactation, 3) contraindications for laparoscopic surgery, such as gastrointestinal diseases of intra-abdominal infection, adhesions, etc., 4) severe heart, liver and kidney dysfunction, 5) organic and systemic diseases intolerant of surgery.

Keywords: laparoscopic sleeve gastrectomy nonalcoholic fatty liver type 2 diabetes polycystic ovary syndrome acanthosis nigricans hyperuricemia hyperinsulinemia sleep apnea syndrome